NOTE: As of 2/16/2023, this table is no longer being updated. For data on COVID-19 Updated (Bivalent) Booster Coverage by Age go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Age-/j2me-7k56. For information on COVID-19 vaccination primary series coverage for people less than 5 years go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccination-Primary-Series-Coverage-Age-L/su9q-qn6e Important change as of June 1, 2022 As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages for state- and county-level tables (except coverage by CT SVI priority zip code). 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator. DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT. This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated, and addition dose 1 by age group. Age is based on age at the time of administration of the first dose. All data in this report are preliminary; data for previous dates will be updated as new reports are received, and data errors are corrected. Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used. In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose. A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations. The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported. Town-level coverage estimates have been capped at 100%. Observed coverage may be greater than 100% for multiple reasons, including census denominator data not including all individuals that currently reside in the town (e.g., part time residents, change in population size since the census), errors in address data or other reporting errors. Also, the percent with at least one dose many be over-estimated, and the percent fully

New weekly allocations of doses are posted every Tuesday. Beginning the following Thursday, states can begin ordering doses from that week’s new allocation of 1st doses. Beginning two weeks (Pfizer) or three weeks (Moderna) from the following Sunday, states can begin ordering doses from that week’s new allocation of 2nd doses. After doses are ordered by states, shipments begin the following Monday. The entire order may not arrive in one shipment or on one day, but over the course of the week.

Second doses are opened up for orders on Sundays, at the appropriate interval two or three weeks later according to the manufacturer’s label, with shipments occurring after jurisdictions place orders.

Shipments of an FDA-authorized safe and effective COVID-19 vaccine continue to arrive at sites across America. Vaccinations began on December 14, 2020.

https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

Moderna Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/b7pe-5nws

Janssen Vaccine Data - https://data.cdc.gov/Vaccinations/COVID-19-Vaccine-Distribution-Allocations-by-Juris/w9zu-fywh

NOTE: This dataset has been retired and marked as historical-only. Weekly rates of COVID-19 cases, hospitalizations, and deaths among people living in Chicago by vaccination status and age. Rates for fully vaccinated and unvaccinated begin the week ending April 3, 2021 when COVID-19 vaccines became widely available in Chicago. Rates for boosted begin the week ending October 23, 2021 after booster shots were recommended by the Centers for Disease Control and Prevention (CDC) for adults 65+ years old and adults in certain populations and high risk occupational and institutional settings who received Pfizer or Moderna for their primary series or anyone who received the Johnson & Johnson vaccine. Chicago residency is based on home address, as reported in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE) and Illinois National Electronic Disease Surveillance System (I-NEDSS). Outcomes: • Cases: People with a positive molecular (PCR) or antigen COVID-19 test result from an FDA-authorized COVID-19 test that was reported into I-NEDSS. A person can become re-infected with SARS-CoV-2 over time and so may be counted more than once in this dataset. Cases are counted by week the test specimen was collected. • Hospitalizations: COVID-19 cases who are hospitalized due to a documented COVID-19 related illness or who are admitted for any reason within 14 days of a positive SARS-CoV-2 test. Hospitalizations are counted by week of hospital admission. • Deaths: COVID-19 cases who died from COVID-19-related health complications as determined by vital records or a public health investigation. Deaths are counted by week of death. Vaccination status: • Fully vaccinated: Completion of primary series of a U.S. Food and Drug Administration (FDA)-authorized or approved COVID-19 vaccine at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Boosted: Fully vaccinated with an additional or booster dose of any FDA-authorized or approved COVID-19 vaccine received at least 14 days prior to a positive test (with no other positive tests in the previous 45 days). • Unvaccinated: No evidence of having received a dose of an FDA-authorized or approved vaccine prior to a positive test. CLARIFYING NOTE: Those who started but did not complete all recommended doses of an FDA-authorized or approved vaccine prior to a positive test (i.e., partially vaccinated) are excluded from this dataset. Incidence rates for fully vaccinated but not boosted people (Vaccinated columns) are calculated as total fully vaccinated but not boosted with outcome divided by cumulative fully vaccinated but not boosted at the end of each week. Incidence rates for boosted (Boosted columns) are calculated as total boosted with outcome divided by cumulative boosted at the end of each week. Incidence rates for unvaccinated (Unvaccinated columns) are calculated as total unvaccinated with outcome divided by total population minus cumulative boosted, fully, and partially vaccinated at the end of each week. All rates are multiplied by 100,000. Incidence rate ratios (IRRs) are calculated by dividing the weekly incidence rates among unvaccinated people by those among fully vaccinated but not boosted and boosted people. Overall age-adjusted incidence rates and IRRs are standardized using the 2000 U.S. Census standard population. Population totals are from U.S. Census Bureau American Community Survey 1-year estimates for 2019. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. This dataset reflects data known to CDPH at the time when the dataset is updated each week. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. For all datasets related to COVID-19, see https://data.cityofchic

NOTE: As of 2/16/2023 this table is no longer being updated. For information on COVID-19 Updated (Bivalent) Booster Coverage, go to https://data.ct.gov/Health-and-Human-Services/COVID-19-Updated-Bivalent-Booster-Coverage-By-Race/8267-bg4w.

Important change as of June 1, 2022

As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages by age at the state level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

• DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020 State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

This table shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated and had additional dose 1 by race / ethnicity and age group.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected. The age groups in the state-level data tables will also be changing as a result of the switch to the new denominator.

Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used.

In the data shown here, a person who has received at least one dose of COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if he/she has completed a primary vaccination series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the people who have received at least one dose.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional monovalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna, Novavax or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed. Bivalent booster administrations are not included in the additional dose 1 calculations.

The percent with at least one dose many be over-estimated, and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Race and ethnicity data may be self-reported or taken from an existing electronic health care record. Reported race and ethnicity information is used to create a single race/ethnicity variable. People with Hispanic ethnicity are classified as Hispanic regardless of reported race. People with a missing ethnicity are classified as non-Hispanic. People with more than one race are classified as multiple races.

A vaccine coverage percentage cannot be calculated for people classified as NH Other race or NH Unknown race since there are not population size estimates for these groups. Data quality assurance activities suggest that in at least some cases NH Other may represent a missing value. Vaccine coverage estimates in specific race/ethnicity groups may be underestimated as result of the classification of records as NH Unknown Race or NH Other Race.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. This includes doses given to residents of CT and to residents of other states vaccinated in CT. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records reported to CT WiZ. However, once CT residents who have received doses in each jurisdiction are added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed.

Note: This dataset takes the place of the original "COVID-19 Vaccinations by Race/Ethnicity" dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/xkga-ifz3 ), which will not be updated after 5/20/2021 and “COVID-19 Vaccinations by Race / Ethnicity” dataset (https://data.ct.gov/Health-and-Human-Services/COVID-19-Vaccinations-by-Race-Ethnicity/ybkg-w5x2), which will not be updated after 10/20/2021.

NOTE: This dataset replaces a previous one. Please see below. Chicago residents who are up to date with COVID-19 vaccines by Healthy Chicago Equity Zone (HCEZ), based on the reported address, race-ethnicity, and age group of the person vaccinated, as provided by the medical provider in the Illinois Comprehensive Automated Immunization Registry Exchange (I-CARE). Healthy Chicago Equity Zones is an initiative of the Chicago Department of Public Health to organize and support hyperlocal, community-led efforts that promote health and racial equity. Chicago is divided into six HCEZs. Combinations of Chicago’s 77 community areas make up each HCEZ, based on geography. For more information about HCEZs including which community areas are in each zone see: https://data.cityofchicago.org/Health-Human-Services/Healthy-Chicago-Equity-Zones/nk2j-663f “Up to date” refers to individuals who meet the CDC’s updated COVID-19 vaccination criteria based on their age and prior vaccination history. For surveillance purposes, up to date is defined based on the following criteria: People ages 5 years and older: ·Are up to date when they receive 1+ doses of a COVID-19 vaccine during the current season. Children ages 6 months to 4 years: · Children who have received at least two prior COVID-19 vaccine doses are up to date when they receive one additional dose of COVID-19 vaccine during the current season, regardless of vaccine product. · Children who have received only one prior COVID-19 vaccine dose are up to date when they receive one additional dose of the current season's Moderna COVID-19 vaccine or two additional doses of the current season's Pfizer-BioNTech COVID-19 vaccine. · Children who have never received a COVID-19 vaccination are up to date when they receive either two doses of the current season's Moderna vaccine or three doses of the current season's Pfizer-BioNTech vaccine. This dataset takes the place of a previous dataset, which cover doses administered from December 15, 2020 through September 13, 2023 and is marked as historical: - https://data.cityofchicago.org/Health-Human-Services/COVID-19-Vaccinations-by-Region-Age-and-Race-Ethni/n7f2-e2kq. Data notes: Weekly cumulative totals of people up to date are shown for each combination of race-ethnicity and age group within an HCEZ. Note that each HCEZ has a row where HCEZ is “Citywide” and each HCEZ has a row where age is "All" and race-ethnicity is “All Race/Ethnicity Groups” so care should be taken when summing rows. Coverage percentages are calculated based on the cumulative number of people in each population subgroup (age group by race-ethnicity within an HCEZ) who are up to date, divided by the estimated number of people in that subgroup. Population counts are from the 2020 U.S. Decennial Census. Actual counts may exceed population estimates and lead to >100% coverage, especially in small race-ethnicity subgroups of each age group within an HCEZ. All coverage percentages are capped at 99%. Summing all race/ethnicity group populations to obtain citywide populations may provide a population count that differs slightly from the citywide population count listed in the dataset. Differences in these estimates are due to how community area populations are calculated. Weekly cumulative counts and coverage percentages are reported from the week ending Saturday, September 16, 2023 onward through the Saturday prior to the dataset being updated. All data are provisional and subject to change. Information is updated as additional details are received and it is, in fact, very common for recent dates to be incomplete and to be updated as time goes on. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources due to when data are reported and how City of Chicago boundaries are defined. The Chicago Department of Public Health uses the most complete data available to estimate COVID-19 vaccinati

This site provides historical data beginning June 14, 2023, for the visualization presented on COVID-19 Data Tracker’s “Vaccinations in the United States” site titled “Percent of Total Population Who Are Up to Date with COVID-19 Vaccines” Definition for Up to Date: For surveillance purposes people are ‘Upto Date’ with COVID-19 vaccines based on the following criteria: People ages 6 years and older: Are up to date if they received 1 updated Pfizer-BioNTech or Moderna COVID-19 vaccine. Children ages 6 months to 5 years who received the Pfizer-BioNTech COVID-19 vaccine: Are up to date if: At ages 6 months to 4 years, they received 3 COVID-19 vaccine doses, including at least 1 updated COVID-19 dose; at age 5 years, they received at least 1 updated COVID-19 vaccine dose. Children ages 6 months to 5 years who received the Moderna COVID-19 vaccine: Are up to date if they received 2 Moderna COVID-19 vaccine doses, including at least 1 updated COVID-19 vaccine dose. People who are unable or choose not to get a recommended mRNA vaccine: Are up to date if they receive the Novavax COVID-19 vaccine doses approved for their age group. CDC uses US Census estimates for the total populations within each specified demographic group regardless of prior vaccination status as denominators. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.

NOTE: As of 2/16/2023, this page is no longer being updated.

Important change as of June 1, 2022

As of June 1, 2022, we will be using 2020 DPH provisional census estimates* to calculate vaccine coverage percentages by gender at the state level. 2020 estimates will replace the 2019 estimates that have been used. Caution should be taken when making comparisons of percentages calculated using the 2019 and 2020 census estimates since observed difference may result from the shift in the denominator.

• DPH Provisional State and County Characteristics Estimates April 1, 2020. Hayes L, Abdellatif E, Jiang Y, Backus K (2022) Connecticut DPH Provisional April 1, 2020, State Population Estimates by 18 age groups, sex, and 6 combined race and ethnicity groups. Connecticut Department of Public Health, Health Statistics & Surveillance, SAR, Hartford, CT.

This tables shows the number and percent of people that have initiated COVID-19 vaccination, are fully vaccinated grouped by gender and have additional dose 1 grouped by gender.

All data in this report are preliminary; data for previous dates will be updated as new reports are received and data errors are corrected.

Population size estimates are based on 2019 DPH census estimates until 5/26/2022. From 6/1/2022, 2020 DPH provisional census estimates are used.

A person who has received at least one dose of any COVID-19 vaccine is considered to have initiated vaccination. A person is considered fully vaccinated if they have completed a primary series by receiving 2 doses of the Pfizer, Novavax or Moderna vaccines or 1 dose of the Johnson & Johnson vaccine. The fully vaccinated are a subset of the number who have received at least one dose. Population estimates are based on 2019 CT population estimates. Bivalent booster administrations are not included in the additional dose 1 calculations.

A person who completed a Pfizer, Moderna, Novavax or Johnson & Johnson primary series (as defined above) and then had an additional bivalent dose of COVID-19 vaccine is considered to have had additional dose 1. The additional dose may be Pfizer, Moderna or Johnson & Johnson and may be a different type from the primary series. For people who had a primary Pfizer or Moderna series, additional dose 1 was counted starting August 18th, 2021. For people with a Johnson & Johnson primary series additional dose 1 was counted starting October 22nd, 2021. For most people, additional dose 1 is a booster. However, additional dose 1 may represent a supplement to the primary series for a people who is moderately or severely immunosuppressed.

The percent with at least one dose may be over-estimated and the percent fully vaccinated and with additional dose 1 may be under-estimated because of vaccine administration records for individuals that cannot be linked because of differences in how names or date of birth are reported.

Connecticut COVID-19 Vaccine Program providers are required to report information on all COVID-19 vaccine doses administered to CT WiZ, the Connecticut Immunization Information System. This includes doses given to residents of CT and to residents of other states vaccinated in CT. Data on doses administered to CT residents out-of-state are being added to CT WiZ jurisdiction-by-jurisdiction. Doses administered by some Federal entities (including Department of Defense, Department of Correction, Department of Veteran’s Affairs, Indian Health Service) are not yet reported to CT WiZ. Data reported here reflect the vaccination records reported to CT WiZ. However, once CT residents who have received doses in each jurisdiction are added to CT WiZ, the records for residents of that jurisdiction vaccinated in CT are removed. For example, when CT residents vaccinated in NYC were added, NYC residents vaccinated in CT were removed.

Note: As part of continuous data quality improvement efforts, duplicate records

As of 10/27/2022, this dataset will no longer update. To continue to access updated vaccination metrics given to SF residents, including newly added bivalent boosters, please navigate to the following page: COVID-19 Vaccinations Given to SF Residents Over Time.

A. SUMMARY This dataset represents the COVID-19 vaccinations given to San Franciscans over time. All vaccines given to people who live in San Francisco are included, no matter where the vaccination took place (the vaccine may have been administered in San Francisco or outside of San Francisco).

B. HOW THE DATASET IS CREATED Information on doses administered to those who live in San Francisco is from the California Immunization Registry (CAIR), run by the California Department of Public Health (CDPH).

C. UPDATE PROCESS Updated daily via automated process

D. HOW TO USE THIS DATASET Different vaccines have different dosage requirements. For example, the Moderna and the Pfizer vaccines require two doses in order for a resident to complete their primary vaccine series (as of December 21, 2021). Each dose is recorded separately in its respective dataset column. Other vaccines, such as Johnson & Johnson, would only require a single dose for a resident to complete their primary vaccine series (as of December 21, 2021). The Pfizer vaccine for children under 5 requires three separate doses. Single dose vaccines counts are recorded in a separate column.

Summing the NEW_1ST_DOSES, NEW_2ND_DOSES, NEW_SINGLE_DOSES columns would give you the total count of primary vaccine series doses administered on a given day. To count the number of individuals who have completed their primary vaccine series on a given day, use the NEW_SERIES_COMPLETED column. To count the number of individuals vaccinated (with any primary series dose) for the first time on a given day, use the NEW_RECIPIENTS column.

To count the number of individuals who got a vaccine booster on a given day, use the NEW_BOOSTER_RECIPIENTS column. To count the number of booster doses administered on a given day, use the NEW_BOOSTER_DOSES column. To count the total number of individuals who have received a booster over time, use the CUMULATIVE_BOOSTER_RECIPIENTS column. To count the total number of booster doses that have been administered over time, use the CUMULATIVE_BOOSTER_DOSES column.

In our public dashboards we combine this dataset with the US Census's 2019 five-year American Community Survey population estimates to estimate the percent of San Franciscans vaccinated.

a - it is not fair to disclose individual’s personal details to the world and is likely to cause damage or distress. b - these details are not of sufficient interest to the public to warrant an intrusion into the privacy of the individual. Please click the below web link to see the exemption in full. www.legislation.gov.uk/ukpga/2000/36/section/40 Breach of Confidentiality Please note that the identification of individuals is also a breach of the common law duty of confidence. An individual who has been identified could make a claim against the NHSBSA for the disclosure of the confidential information. The information requested is therefore being withheld as it falls under the exemption in section 41(1) ‘Information provided in confidence’ of the Freedom of Information Act. Please click the below web link to see the exemption in full. Question 1 How many claims have been made to the VDPS due to an adverse reaction to a covid vaccine to date? 16,824 claims have been received by the Vaccine Damage Payment Scheme (VDPS). Question 2– How many claimants have been notified of an outcome? 8,806 claimants have been notified of an outcome. Question 3 – Please provide a breakdown of the vaccines involved in the claims that have received an outcome? Of the 8,806 claims which have received an outcome, 4,107 relate to AstraZeneca, 3,034 relate to Pfizer, 445 relate to Moderna and 1,220 relate to other vaccines, or more than one COVID-19 vaccine and therefore we are unable to categorise them. For example, where a claim relates to an initial vaccine from one manufacturer and a booster from another. Question 4 – How many claims have been successful? Please provide a breakdown of which vaccine were used in the claims awarded. Since disclosure of FOI-02252 whereby 188 claimants were notified they were entitled to a Vaccine Damage Payment, this number has increased by fewer than 5. Of the total number of successful claimants, fewer than five were Pfizer and Moderna and the remaining claims were AstraZeneca. Therefore, as detailed above in accordance with section 40 (2) and section 41 of FOIA, we are unable to provide an updated breakdown by manufacturer. Question 5– How many claims have been rejected / unsuccessful? Please be advised since the disclosure of FOI-02252 where we disclosed 7,748 claims have been rejected, and a further 716 did not meet the criteria for medical assessment, these figures have increased by fewer than five. We have therefore decided not to disclose this exact figure under section 40 (2) and section 41 of the FOIA because the small changes in numbers when compared to figures provided previously could result in claimants being identified. Details of these exemptions are outlined above. Question 6a – What are the reasons for claims being rejected (causation, not meeting 60% threshold, ineligible to claim.) Please provide numbers? Please provide a breakdown of which vaccine was used in the claims when causation was accepted.

This dataset is no longer updated, find vaccination data here From 24 March 2022, Public Health Scotland (PHS) began reporting the number of people who have received a fourth dose of Covid-19 vaccination. Vaccine uptake statistics among care home residents and those who are severely immunosuppressed will be reported initially. PHS will include further updates as the Spring/Summer vaccination programme rolls out. In addition, as part of our continuous review of reporting, PHS made some changes to vaccine uptake statistics. From 24 March 2022, the deceased and those who no longer live in Scotland are no longer be included in vaccine uptake statistics. Historic trend data have been updated to take into account this new methodology for all apart from the Daily Trends by JCVI Priority Group table (more details about the data in this table are below). Scotland level data for all vaccinations administered (i.e. including those who have since died or moved from Scotland) are still available in the Daily Trend of All Vaccinations Delivered in Scotland table. Also from 24 March 2022, Dose 3/Booster doses are termed "Dose 3". To allow new data to be fully processed and available at 14:00, the Daily COVID-19 in Scotland and COVID-19 Vaccination in Scotland datasets will be temporarily unavailable from 12:45 to 14:00. During this window, the datasets will not be visible and any queries made to these datasets will return a 404 - Not found error. At all other times the datasets will be available in full as usual. PHS reviewed the JCVI priority group uptake figures from 18 November 2021, specifically how we derive the numerator and the denominator. The rational for the change is to ensure we report on most up to date living population for each group. For this, the list of individuals in each cohort has been refreshed to be more current. We have also removed individuals who have since died to reflect the current living population. From the 24 March 2022 those who are no longer living in Scotland have also been removed from the numerator and denominator for JCVI priority group uptake figures. This means all the JCVI cohorts and populations have changed for both numerator and denominators on these two dates and care should be taken when interpreting trends. On 08 December 2020, a Coronavirus (COVID-19) vaccine developed by Pfizer BioNTech (Comirnaty) was first used in the UK as part of national immunisation programmes. The AstraZeneca (Spikevax) vaccine was also approved for use in the national programme, and rollout of this vaccine began on 04 January 2021. Moderna (Vaxzevria) vaccine was approved for use on 8 January 2021 and rollout of this vaccine began on 07 April 2021. These vaccines have met strict standards of safety, quality and effectiveness set out by the independent Medicines and Healthcare Products Regulatory Agency (MHRA). Those giving the vaccine to others were the first to receive the vaccination. In the first phase of the programme, NHS Scotland followed the independent advice received from the Joint Committee on Vaccination and Immunisation (JCVI) and prioritised delivery of the vaccine to those with the greatest clinical need, in line with the recommended order of prioritisation. For booster vaccinations a similar approach has been adopted. Definitions used in the vaccine uptake by JCVI priority group resource can be found in the JCVI Priority Group Definitions table. Individuals can appear in more than one JCVI priority group. This dataset provides information on daily number of COVID vaccinations in Scotland. Data on the total number of vaccinations in Scotland is presented by day administered and vaccine type, by age group, by sex, by non-age cohorts and by geographies (NHS Board and Local Authority). As the population in the cohorts can change with time, these will be refined when updated data are available. Additional data sources relating to this topic area are provided in the Links section of the Metadata below. Data visualisation and additional notes are available on the Public Health Scotland - Covid 19 Scotland dashboard.